Search Results for :


Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in Stage I and II Cohort Study at 2016 AAD Summer Meeting

Boston, MA—July 28, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test DecisionDx®-Melanoma in a cohort of 356 Stage I and II melanoma patients. The data confirm findings from two previously published multicenter clinical … Read More


Results of New Study with Castle Biosciences’ Skin Melanoma Gene Expression Test Published in Current Medical Research and Opinion

Friendswood, TX—July 11, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the publication of a prospectively designed, multicenter, decision impact study of its gene expression profile (GEP) test for cutaneous melanoma. The DecisionDx®-Melanoma GEP test accurately predicts metastatic risk independent of current diagnostic modalities including AJCC staging. … Read More


Castle Biosciences Selected to Showcase Thriving Texas Biotechnology and Life Sciences Industries at BIO International Convention

Castle Biosciences was recently selected by the Texas Governor’s office to help showcase the state’s growing biotechnology and life sciences industries at a state-sponsored exhibit at the 2016 BIO International Convention, the largest global biotechnology event. The Company was featured among industry leaders in Texas such as the Cancer Prevention Research Institute of Texas (CPRIT), … Read More


Castle Biosciences Announces Clinical Results of Melanoma Gene Expression Test in 334-Patient Performance Cohort Study at ASCO 2016

Results confirm accuracy of DecisionDx-Melanoma to identify recurrence risk
A second independent, prospective study confirms test accuracy
Chicago, IL—June 6, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced the results from a study evaluating the performance of its gene expression profile (GEP) test, DecisionDx®-Melanoma, in 334 new melanoma … Read More


Castle Biosciences Announces New Clinical Data Presentations at ASCO 2016 Underscoring the Accuracy and Clinical Utility of Gene Expression Profile Test for Cutaneous Melanoma

Three data presentations focused on studies of DecisionDx-Melanoma test
Company will also present data on test in development for predicting cancer
recurrence in soft tissue sarcoma
Friendswood, TX—May 19, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced that several abstracts on the Company’s gene expression profile (GEP) tests … Read More


Castle Biosciences Announces New Clinical Data to be Presented at ASCO 2016 Confirming Performance of DecisionDx-UM Gene Expression Profile (GEP) Test in Uveal Melanoma

Friendswood, TX—May 19, 2016—Castle Biosciences, Inc., a provider of molecular diagnostics to improve cancer treatment decisions, today announced new clinical data on DecisionDx®-UM, its gene expression profile (GEP) test to predict metastasis in patients diagnosed with uveal melanoma. The new data will be highlighted in a presentation at the 2016 American Society of Clinical Oncology … Read More